Joe Duarte

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert and Weekly Cash Machine.  He has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

I am increasing the Buy limit on Opko Health (OPK), a diversified health care company focused on renal diseases and precise laboratory testing, from to $11 to $12 as the company beat its quarterly earnings expectation and gave upbeat guidance on its August 8 earnings release.  I am leaving the… Read More

The health care sector is about to get bumpy with some stocks flourishing while others fall on hard times.  Just in the past week we saw a totally different set of reactions to earnings reports as shares of Cerus Corp. (Nasdaq: CERS) sidestepped bad news and rallied while Emergent BioSolutions… Read More

I am recommending the sale of Novo Nordisk NYSE: (NVO) and Emergent BioSolutions (NYSE: EBS).  Both companies failed to meet expectations and are likely to run into further headwinds as the biotech and healthcare dynamic changes gears and price cutting pressure in the U.S. starts to gather steam.Emergent BioSolutions Inc. Read More

Shares of Seres Therapeutics (Nasdaq: MCRB), a research stage biotech company looking to treat gut related diseases by using the body’s own bacteria fell over 60% on July 29 as the company announced disappointing results of its SER-109 Phase II clinical trial against the disease causing gut bacteria Clostridium difficile… Read More

Shares of Cerus Corp. (Nasdaq: CERS) and Rollins Inc. (NYSE: ROL) moved higher on July 29 (and are higher in this morning’s trading) in response to the developing story in the state of Florida with regard to the Zika virus.  Rollins Inc. is the leading global pest control company, operating… Read More

Shares of Seres Therapeutics (Nasdaq: MCRB), a research stage biotech company looking to treat gut related diseases by using the body’s own bacteria,  were down sharply in early trading on July 29 as the company announced disappointing results of its SER-109 clinical trial against the disease causing gut bacteria Clostridium… Read More

If you own shares of Emergent BioSolutions (NYSE: EBS) you will notice some changes in your portfolio including ownership in shares of a company named Aptevo Therapeutics (Nasdaq: APVO) on August 1. That’s because EBS is spinning off Aptevo, its oncology division. This could create some tax related issues in… Read More

Shares of Medidata Solutions (Nasdaq: MDSO), the leading cloud analytic software company for the biotech research space, rallied after beating earnings expectations by one cent and reaffirming its forward guidance.    The company reported results of Q2 EPS of $0.24, versus expectations of $0.23. Revenue for the quarter came in at… Read More